Autosomal Dominant Severe Congenital Neutropenia (AD-SCN)

Autosomal dominant severe congenital neutropenia (AD-SCN) is a rare, inherited immune disorder present from birth in which the body has very low numbers of neutrophils, a type of white blood cell that fights bacteria and fungi. In AD-SCN, a single altered copy of a gene (most often the ELANE gene) is enough to cause lifelong, severe neutropenia. Babies and children develop frequent, serious infections because their bone marrow makes neutrophils that either die too early or fail to mature. Without care, infections can be life-threatening. With careful monitoring, antibiotics when needed, and medications like G-CSF (granulocyte colony-stimulating factor) in many cases, people can live safer lives; however, there is a recognized long-term risk of bone-marrow changes such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), so ongoing follow-up is essential. MedlinePlus+2NCBI+2

Autosomal dominant severe congenital neutropenia is a lifelong condition present from birth in which the body makes very few neutrophils—white blood cells that fight germs—so infections happen easily and often. The most common inherited cause is a change (mutation) in a gene called ELANE, which affects a protein (neutrophil elastase) that developing neutrophils need to mature normally in the bone marrow. Because the bone marrow cannot finish making neutrophils, the absolute neutrophil count (ANC) is very low (often <500/µL), and babies and young children can have fevers, mouth ulcers, gum disease, pneumonias, skin and deep tissue infections. Over time, people with SCN are also watched closely for bone-marrow problems like myelodysplastic syndrome or acute myeloid leukemia, especially if very high doses of growth factor are needed. NCBI+2MedlinePlus+2

“Autosomal dominant” means a child has a 1 in 2 (50%) chance to inherit the condition if one parent carries the ELANE change. Genetic testing confirms the cause. Some families have ELANE-negative SCN or other genes; but ELANE is the most frequent autosomal-dominant form. NCBI

Other names

Doctors may also use the terms “congenital agranulocytosis,” “congenital neutropenia,” “severe congenital neutropenia (SCN),” and in some historical descriptions “Kostmann disease/syndrome.” Because SCN includes several inheritance patterns (autosomal dominant, autosomal recessive, and X-linked), calling the autosomal-dominant form out clearly helps guide genetic counseling. MedlinePlus

Types

SCN is a group of disorders with shared features (very low absolute neutrophil count, early-onset infections) but different genetic causes and inheritance. The autosomal dominant type is most frequently linked to ELANE variants and, less commonly, to GFI1 or SRP54. Other SCN genes exist (e.g., HAX1, JAGN1, G6PC3, VPS45), but those usually follow recessive or other patterns. Pinpointing the gene helps with prognosis, family planning, and targeted monitoring for complications. NCBI+1

---

Causes

1. ELANE variants (neutrophil elastase): The most common cause of AD-SCN. Misfolded elastase stresses developing neutrophils in the marrow, causing them to die before maturing, which keeps counts very low. NCBI+1

2. GFI1 variants: Changes in this transcription factor disrupt the genetic program neutrophils need to mature, producing severe neutropenia with autosomal-dominant inheritance in some families. MedlinePlus

3. SRP54 variants (signal recognition particle 54): De novo or inherited autosomal-dominant SRP54 changes impair protein targeting in neutrophil precursors, leading to maturation arrest and chronic neutropenia. Orpha

4. ELANE “dominant-negative” effects: Some ELANE changes not only remove normal function but also actively interfere with the healthy copy, amplifying cell stress and death in neutrophil precursors. ASH Publications

5. ER stress and unfolded-protein response: Misfolded neutrophil elastase in ELANE-SCN overloads the cell’s protein-folding machinery, triggering cell-death pathways during neutrophil development. ASH Publications

6. Apoptosis signaling in myeloid precursors: Many SCN variants converge on pathways that push early neutrophil cells toward apoptosis (programmed death), explaining the marrow “maturation arrest.” PMC

7. Secondary CSF3R changes during disease course: While not the germline cause of AD-SCN, acquired CSF3R mutations can emerge over time and are linked to progression toward MDS/AML in some patients. ASH Publications

8. RUNX1 cooperation in leukemic evolution: Acquired RUNX1 changes can cooperate with CSF3R mutations in SCN to drive excessive proliferation and leukemia transformation. ASH Publications

9. Marrow microenvironment stress: Chronic infection and inflammatory signaling in SCN can worsen marrow stress and neutrophil loss, compounding the primary genetic defect. PMC

10. G-CSF receptor signaling imbalance (disease biology): Even without receptor mutations at birth, disturbed downstream signaling is part of the SCN biology; in some, later CSF3R lesions alter this axis further. PMC

11. Transcriptional reprogramming of granulopoiesis: Master regulators affected by AD genes (e.g., GFI1) tilt precursor cells away from healthy neutrophil development. PMC

12. Proteotoxicity from mutant neutrophil proteins: Faulty proteins (e.g., mutant elastase) accumulate, damaging developing cells and triggering quality-control pathways that end in cell death. ASH Publications

13. Inflammasome and stress-granule signaling: Experimental work shows abnormal stress signaling contributes to the block in neutrophil maturation in SCN models. ASH Publications

14. Gene dosage and variable expressivity: Because AD conditions require only one altered copy, small differences in gene expression can influence how severe the neutropenia and infections become. NCBI

15. De novo dominant variants: A child may be the first in the family with an autosomal-dominant ELANE (or SRP54) change, so a negative family history does not rule out AD-SCN. NCBI+1

16. Pathway convergence across AD genes: Different AD genes disturb the same final pathway—neutrophil maturation—so clinical pictures can overlap even when the gene differs. PMC

17. Constitutional marrow maturation arrest: The hallmark marrow finding in SCN—cells stopping around the promyelocyte/myelocyte stage—is a direct effect of these dominant variants. PMC

18. High cellular turnover in the marrow: The body tries to make neutrophils fast, but defective precursors die quickly; the result is persistently low counts. PMC

19. Genotype–phenotype diversity in ELANE: Different ELANE mutations can present as cyclic neutropenia, SCN, or intermediate patterns; the AD mechanism is shared, but severity varies. NCBI

20. Rarity and under-recognition: Because AD-SCN is ultra-rare, delayed recognition can worsen infection burden before diagnosis and care begin, despite a clear genetic basis. Orpha

---

Symptoms

1) Recurrent skin infections: Cellulitis, boils, or abscesses happen again and again because neutrophils are too few to contain bacteria at the skin barrier. MedlinePlus

2) Mouth ulcers and gingivitis: Painful ulcers, gum swelling, and early periodontitis are common because oral bacteria overgrow without neutrophil control. MedlinePlus

3) Ear infections (otitis media): Infants and toddlers with SCN often have repeated ear infections that may resist standard treatment. NCBI

4) Pneumonia: Lung infections can be severe or recurrent, sometimes needing hospitalization and IV antibiotics. NCBI

5) Sinus infections: Chronic or frequent sinusitis develops because airway bacteria are not cleared efficiently. NCBI

6) Fever without a clear source: With very low neutrophils, even small infections can cause high fevers; any fever needs urgent medical review. MedlinePlus

7) Perianal infections: Painful redness, fissures, or abscesses near the anus are typical in SCN. MedlinePlus

8) Liver or deep-organ infections: Serious, sometimes unexpected organ infections can occur because first-line cellular defenses are weak. NCBI

9) Poor weight gain during repeated illness: Frequent infections may interrupt feeding and growth in infants and young children. MedlinePlus

10) Bone pain during infections: Inflammation from recurrent infections can cause aches and pains. MedlinePlus

11) Fatigue: Ongoing infections and inflammation make children appear tired or less active. MedlinePlus

12) Skin pustules or furuncles: Small pus-filled bumps reflect neutrophil-dependent processes that are impaired in SCN. MedlinePlus

13) Sepsis risk: With severe neutropenia, minor infections can spread into the bloodstream quickly; urgent care is needed for fevers. ASH Publications

14) Persistent nasal crusting or discharge: Chronic colonization and infection of the nose occur when neutrophil function is low. NCBI

15) Oral thrush or fungal infections: Neutropenia also increases the risk of candida and other fungal infections, especially with antibiotics. MedlinePlus

---

Diagnostic tests

A) Physical examination

1) Full skin and soft-tissue exam: The clinician looks for boils, abscesses, cellulitis, surgical-like scars from prior drainage, and fungal rashes—clues to chronic neutrophil deficiency. MedlinePlus

2) Oral and dental exam: Ulcers, swollen or bleeding gums, tooth loosening, and periodontal disease are classic in chronic severe neutropenia. MedlinePlus

3) ENT and chest exam: Ear, nose, throat, and lung findings (otitis, sinus tenderness, crackles) suggest recurrent airway infections. NCBI

4) Abdominal exam: Liver enlargement or tenderness may hint at deep infections or abscesses needing imaging. NCBI

5) Growth and vital signs: Fever, tachycardia, and poor growth during illness episodes point to high infectious burden from neutropenia. MedlinePlus

B) “Manual” bedside tests and procedures

6) Wound swab and culture: Simple bedside sampling helps target antibiotics and documents unusual or resistant organisms in recurrent infections. PMC

7) Blood cultures during fever: Obtained promptly at fever onset to detect bloodstream infection; essential in severe neutropenia. ASH Publications

8) Lumbar puncture (when indicated): If symptoms suggest meningitis, bedside CSF sampling confirms infection and guides therapy. PMC

C) Laboratory and pathological tests

9) Complete blood count (CBC) with differential: Confirms severe neutropenia (often ANC < 0.5 × 10⁹/L), the defining feature of SCN, and tracks response over time. Orpha

10) Serial CBCs: Repeated counts show persistence of severe neutropenia from infancy and help distinguish SCN from transient or cyclic patterns. NCBI

11) Bone marrow aspirate/biopsy: Classic maturation arrest at the promyelocyte/myelocyte stage confirms SCN biology and rules out other marrow failure syndromes. PMC

12) Cytogenetics/NGS panel of marrow or blood: Detects acquired changes (e.g., monosomy 7, CSF3R/RUNX1) that signal evolving MDS/AML risk and guide timing of transplant referral. ASH Publications

13) Germline genetic testing (ELANE first): Sequencing confirms the autosomal dominant cause (often ELANE), supports family counseling, and informs prognosis. NCBI

14) Extended gene panels: When ELANE is negative, panels including GFI1, SRP54 and other SCN genes help identify rarer AD variants or exclude recessive/X-linked causes. Orpha

15) Inflammatory markers (CRP/ESR, procalcitonin): Gauge infection severity and response to antibiotics in febrile episodes. PMC

16) Liver and renal function tests: Monitor organ impact of infections and medications during acute care. PMC

17) Immunoglobulins and vaccine titers (selected cases): Check broader immune status if infections are unusually frequent or include atypical organisms. PMC

D) Electrodiagnostic / physiologic monitoring

18) Continuous pulse oximetry during serious infections: Tracks oxygen levels if pneumonia or sepsis is suspected; falls in saturation signal need for urgent escalation. (Electrodiagnostic tools are not disease-specific for SCN, but monitoring is vital in severe infections.) ASH Publications

19) Electrocardiogram (ECG) in sepsis care: Identifies sepsis-related rhythm issues, electrolyte disturbances, or drug effects when patients are acutely ill. ASH Publications

20) Blood pressure and lactate monitoring: While not “diagnosing” SCN itself, these bedside physiologic metrics help detect shock early in neutropenic sepsis. ASH Publications

E) Imaging tests

21) Chest X-ray: Rapid screening for pneumonia in a febrile neutropenic patient with cough or fast breathing. NCBI

22) Ultrasound of soft tissue or abdomen: Detects abscesses, liver lesions, or fluid collections that need drainage or targeted therapy. PMC

23) CT scan (chest/sinuses/abdomen): Provides detailed views for deep or recurrent infections not fully explained by exam or X-ray. PMC

24) Dental panoramic imaging (selected cases): Assesses periodontal bone loss in severe, chronic oral disease due to neutropenia. MedlinePlus

25) MRI (when CNS or deep tissue infection suspected): Defines complicated infections when neurological signs or deep organ involvement is present. PMC

Non-pharmacological treatments (therapies & “other” supports)

Each item: description, purpose, simple mechanism. (Real-world care is personalized; your hematologist will tailor these.)

1. Hand hygiene routine – Wash hands with soap and water (or alcohol rub) for everyone in the home, especially before eating and after bathroom/diaper changes. Purpose: cut germ transfer. Mechanism: removes/denatures microbes on skin. CDC

2. Oral & dental care plan – Soft toothbrush 2–3×/day, floss gently, antiseptic or saline rinses; prompt dental visits for sores/bleeding. Purpose: prevent gingivitis/ulcers that are common in SCN. Mechanism: lowers mouth bacterial load and mucosal breaks. NCBI

3. Skin protection & wound care – Daily bathing, moisturizers, quick cleaning and covering of any cuts, and early evaluation of redness/swelling. Purpose: stop skin infections and abscesses. Mechanism: keeps skin barrier intact and lowers bacterial entry. MedlinePlus

4. Safe food handling (not a strict “neutropenic” diet) – Wash produce, cook meats/eggs fully, avoid unpasteurized dairy/juices and buffets; focus on kitchen cleanliness. Purpose: reduce food-borne infection risk without unnecessary restrictions. Mechanism: minimizes ingestion of high-load/pathogenic bacteria. (Strict “neutropenic diets” haven’t shown benefit; safe-food counseling is recommended.) Andeal+2PMC+2

5. Household & school vaccination (inactivated vaccines up to date) – Keep routine immunizations current for the patient (inactivated vaccines) and all close contacts (including influenza, COVID-19). Purpose: lower exposure and severity. Mechanism: herd protection and individual immune priming. CDC

6. “Fever plan” education – Teach family to check temperature and to go immediately for medical care if oral temp ≥38.3 °C (101 °F) once or ≥38.0 °C (100.4 °F) for ≥1 hour. Purpose: start antibiotics early if febrile neutropenia occurs. Mechanism: early sepsis control saves lives. IDSA

7. Masking during outbreaks/crowding – Use a well-fitting mask in clinics, crowded indoor areas, or during community outbreaks. Purpose: reduce respiratory pathogen exposure. Mechanism: barrier against droplet/aerosol spread. CDC

8. Environmental hygiene – Disinfect high-touch surfaces, avoid second-hand smoke, ensure good ventilation. Purpose: fewer microbes and triggers. Mechanism: lowers environmental bioburden/air irritants. CDC

9. Central-line avoidance when possible and CLABSI-prevention if needed – If a line is required, follow sterile dressing changes and bundle care. Purpose: prevent bloodstream infections. Mechanism: reduces line colonization and entry of pathogens. CDC

10. Early infection reporting – Teach to call for new cough, pain on urination, skin redness, mouth sores, or any fever. Purpose: catch infections before they spread. Mechanism: prompt evaluation and cultures. PMC

11. Travel and pet safety – Avoid contact with animal waste; wash hands after handling pets; avoid reptile pets; drink safe water when traveling. Purpose: limit zoonotic/enteric infections. Mechanism: reduces exposure to Salmonella and others. CDC

12. Nasal saline/humidification – Keep nasal passages moist to limit cracks/bleeding. Purpose: reduce entry points for bacteria. Mechanism: maintains mucosal barrier. PMC

13. Sun-burn/skin-break prevention – Use sunscreen and protective clothing to avoid skin damage that can get infected. Purpose: fewer portals of entry. Mechanism: preserves epidermal barrier. MedlinePlus

14. Activity & rest balance – Normal play/school with common-sense precautions; rest when ill. Purpose: growth and quality of life while staying safe. Mechanism: supports overall resilience and recovery. Cincinnati Children’s

15. Nutrition counseling – Emphasize protein, fruits/vegetables (well-washed/cooked as needed), and adequate calories; avoid unpasteurized foods. Purpose: support growth and immune health. Mechanism: provides substrates for hematopoiesis and healing. Andeal

16. Psychosocial support – Family education, school letters/plans, and support groups/registries (e.g., SCNIR). Purpose: reduce stress and improve adherence. Mechanism: builds coping and care continuity. severe-chronic-neutropenia.org

17. Genetic counseling – Discuss inheritance (50% risk), family testing, and reproductive options (prenatal or preimplantation testing). Purpose: informed family planning. Mechanism: uses known ELANE variant for targeted testing. NCBI

18. Regular CBC and marrow monitoring – Scheduled labs and, when needed, bone marrow exams to watch dose response and screen for MDS/AML signs. Purpose: safety. Mechanism: detects clonal changes and guides therapy. PMC

19. Antimicrobial stewardship plan – Clear rules for when to culture and when to start/stop antibiotics to avoid resistance. Purpose: effective, safe infection care. Mechanism: targets therapy to proven/suspected organisms. PMC

20. HSCT evaluation when indicated – Early referral if poor G-CSF response, very high G-CSF dose needs, or clonal evolution. Purpose: potential cure and lower leukemia risk in selected ELANE patients. Mechanism: replaces defective marrow with healthy donor stem cells. Nature

---

Drug treatments

Important truth up front: For SCN specifically, G-CSF (filgrastim) products are the only agents FDA-approved to reduce the complications of severe chronic neutropenia (including congenital neutropenia). Other medicines below are either biosimilar forms of filgrastim with the same SCN indication, or supportive anti-infectives used when infections occur (approved for infections, not for SCN itself). I label off-label situations clearly. FDA Access Data+2FDA Access Data+2

Core SCN therapy (filgrastim family; on-label for congenital neutropenia):

1. Filgrastim (NEUPOGEN®) – Daily or twice-daily subcutaneous G-CSF that stimulates the bone marrow to make neutrophils, reducing fever, infections, and mouth ulcers in symptomatic congenital, cyclic, or idiopathic severe chronic neutropenia. Typical starting dose in congenital neutropenia: 6 mcg/kg twice daily; dose is individualized to keep ANC in a safe range; monitoring for bone pain, splenomegaly, and very rare splenic rupture is standard. Long-term use lowered sepsis deaths but patients still need leukemia surveillance. Class: hematopoietic growth factor (G-CSF). Side effects: bone pain, leukocytosis, splenomegaly; rare rupture. Source: FDA label and updates. FDA Access Data

2. Filgrastim-sndz (ZARXIO®) – Biosimilar to filgrastim with the same SCN indication and starting dose for congenital neutropenia 6 mcg/kg twice daily, titrated to ANC goals. Purpose/mechanism: identical clinical use; stimulates neutrophil production. Side effects/monitoring: as filgrastim. Source: FDA label. FDA Access Data

3. Filgrastim-aafi (NIVESTYM®) – Biosimilar filgrastim approved for severe chronic neutropenia including congenital SCN; dosing/monitoring mirror Neupogen. Purpose/mechanism: G-CSF to increase neutrophils and prevent infections. Side effects: bone pain, leukocytosis, splenic issues (rare). Source: FDA label/approval letter. FDA Access Data+1

4. Filgrastim-ayow (RELEUKO®) – Biosimilar filgrastim with SCN indication and explicit note that rarely, congenital neutropenia may need ≥100 mcg/kg/day; careful CBC monitoring during initiation and dose changes is advised. Purpose/mechanism/side effects: as above. Source: FDA labels. FDA Access Data+1

Note on pegfilgrastim and tbo-filgrastim: Pegfilgrastim products are approved for chemotherapy-induced neutropenia, not for congenital SCN maintenance. Tbo-filgrastim (GRANIX®) is approved for chemo-related neutropenia, not SCN. They are listed here only to clarify scope. FDA Access Data+1

Supportive anti-infective therapy when fever/infection occurs (indicated for infections; off-label relative to “treat SCN”): Empiric choices follow IDSA/oncology fever-neutropenia standards and are tailored to cultures, allergies, and local resistance.

5. Cefepime (IV anti-pseudomonal cephalosporin) – Used as first-line empiric monotherapy for febrile neutropenia to cover gram-negatives including Pseudomonas while awaiting cultures. Purpose: rapid sepsis control. Mechanism: β-lactam that inhibits bacterial cell wall synthesis. Side effects: neurotoxicity in renal failure, allergy. Source: FDA label (for severe infections); guideline support for empiric FN use. PMC

6. Piperacillin-tazobactam (IV) – Broad anti-pseudomonal coverage including anaerobes; alternative empiric monotherapy for FN. Purpose/mechanism: β-lactam + β-lactamase inhibitor to block cell-wall synthesis and resistance. Side effects: electrolyte load, allergy. Source: IDSA FN guidance for empiric therapy. PMC

7. Meropenem (IV carbapenem) – For centers with high ESBL risk or clinical deterioration. Purpose: very broad empiric coverage. Mechanism: carbapenem cell-wall inhibitor. Side effects: seizures (rare), diarrhea. Source: IDSA FN guidance. PMC

8. Vancomycin (IV) – Add-on if catheter infection, MRSA risk, severe mucositis, or clinical instability. Purpose: cover resistant gram-positives. Mechanism: cell-wall inhibition. Side effects: nephrotoxicity, “red man” reaction. Source: IDSA FN guidance. PMC

9. Antifungal therapy (e.g., voriconazole, liposomal amphotericin B) – Escalation for persistent fever ≥4–7 days or specific fungal findings. Purpose: treat invasive molds/yeasts. Mechanism: ergosterol pathway disruption (vori) or membrane binding (AmB). Side effects: liver enzyme elevations, visual changes (vori); nephrotoxicity (AmB). Source: FN escalation principles. PMC

10. Acyclovir (or valacyclovir) – For clear herpesvirus reactivation (e.g., HSV stomatitis) in SCN. Purpose: shorten viral illness and mucosal breaks. Mechanism: viral DNA polymerase inhibition. Side effects: renal crystalluria (hydrate). Source: antiviral standards in neutropenic hosts. PMC

11. Topical chlorhexidine oral rinses – Reduce oral bacterial load when ulcers/gingivitis flare. Purpose: fewer mouth infections. Mechanism: disrupts bacterial membranes. Side effects: taste change, staining. Source: supportive oral care in neutropenia. NCBI

12. Topical mupirocin – For limited skin breaks/impetigo while awaiting cultures, per clinician judgment. Purpose: reduce local bacterial load. Mechanism: protein synthesis inhibition (isoleucyl-tRNA synthetase). Side effects: local irritation. Source: standard SSTI care (supportive). PMC

13. IVIG (intravenous immunoglobulin) – Selective use if specific antibody deficiency or recurrent bacterial sinopulmonary infections despite ANC response; not a standard SCN therapy. Purpose: raise protective antibodies. Mechanism: passive immunity. Side effects: headache, aseptic meningitis (rare). Source: general immunodeficiency practice. PMC

14. Trimethoprim-sulfamethoxazole (TMP-SMX) – Targeted therapy/prophylaxis in defined scenarios (e.g., recurrent Staph/gram-negative UTIs, Pneumocystis risk by clinician judgment). Purpose: prevent/treat specific infections. Mechanism: folate pathway inhibition. Side effects: rash, marrow suppression (monitor). Source: antimicrobial standards. PMC

15. Amoxicillin-clavulanate (oral) – Step-down therapy after IV control for sensitive organisms when appropriate. Purpose: complete treatment outpatient. Mechanism: cell-wall inhibition + β-lactamase inhibitor. Side effects: GI upset, rash. PMC

16. Clindamycin (oral/IV) – For anaerobic coverage/skin-soft tissue infections in penicillin-allergic patients, if culture-directed. Purpose: bridge or targeted therapy. Mechanism: ribosomal protein synthesis inhibition. Side effects: C. difficile risk. PMC

17. Azithromycin (oral/IV) – Used only for specific atypical infections or as adjunct per cultures (not for neutropenia itself). Mechanism: macrolide ribosomal inhibition. Side effects: QT prolongation. PMC

18. Fluoroquinolone prophylaxis (e.g., levofloxacin) – Sometimes used for high-risk prolonged neutropenia in oncology; not routine in SCN kids unless a specialist advises (resistance/side-effects). Purpose: reduce gram-negative bacteremia in selected cases. Mechanism: DNA gyrase inhibition. Side effects: tendinopathy, QT. Source: ASCO/IDSA prophylaxis guidance context. IDSA

19. Sargramostim (GM-CSF; LEUKINE®) – Not approved for SCN; approved for AML/BMT recovery and H-ARS. May be considered in special off-label scenarios if G-CSF intolerance/non-response, under specialist care. Mechanism: stimulates myeloid recovery (broader than G-CSF). Side effects: edema, capillary leak, leukocytosis. Source: FDA label. FDA Access Data

20. Antipyretics (e.g., acetaminophen) – Symptom control after cultures/antibiotics started (avoid masking fever before evaluation). Purpose: comfort, lower fever. Mechanism: central COX inhibition. Side effects: hepatic risk at high doses. Source: FN care principles. PMC

---

Dietary molecular supplements

No supplement treats SCN. Use only with your clinician to avoid interactions. Evidence is mixed; the safest, most helpful “diet strategy” is safe-food handling and balanced nutrition (see above).

1. Vitamin D (target sufficiency per labs) – May help innate immune balance and neutrophil function when deficient. Dose: individualized to reach sufficient 25-OH-D. Function/mechanism: modulates innate and adaptive immunity; laboratory and clinical data suggest effects on neutrophil activity/NETs; benefit is strongest when correcting deficiency. PMC+2MDPI+2

2. Zinc (only if deficient) – Dose: per age/labs; do not exceed recommended intake. Function/mechanism: zinc is essential for neutrophil chemotaxis, oxidative burst, and barrier integrity; both deficiency and excess can impair neutrophil function. MDPI+1

3. Protein-adequate diet (not a pill, but critical) – Intake: age-appropriate daily protein. Function/mechanism: amino acids support bone-marrow cell production and tissue repair. (Dietary counseling over “restriction” is recommended; see safe-food guidance.) Andeal

4. Omega-3 fatty acids (food first; supplements only if advised) – Function/mechanism: may modulate excessive inflammation; evidence in neutrophil function is mixed; prioritize fish cooked safely. Frontiers

5. Vitamin C (if intake is low) – Function/mechanism: antioxidant support and collagen synthesis for mucosal/skin barriers; high doses can cause GI upset/kidney stones. Evidence for infection prevention is limited outside deficiency. PMC

6. Folate & B12 (correct deficiencies) – Function/mechanism: needed for DNA synthesis in marrow; deficiency can worsen cytopenias; supplement per labs. PMC

7. Iron (only if deficient) – Mechanism: supports erythropoiesis; does not fix neutropenia, and excess iron can foster infections—use only if iron-deficiency anemia is present. PMC

8. Probiotics: generally avoid without specialist advice – In neutropenia, probiotics can rarely cause bacteremia/fungemia and haven’t shown consistent benefit; many centers advise avoiding probiotic products during severe neutropenia. ScienceDirect+1

9. Safe hydration – Clean, filtered/boiled potable water; prevents GI infections and supports circulation during illness. Andeal

10. Multivitamin (age-appropriate, if diet is suboptimal) – Mechanism: modest back-up to cover possible gaps; avoid mega-doses. Andeal

---

Immunity-booster / regenerative / stem cell drugs

Reality check: The FDA has no approved “stem-cell drugs” or regenerative pills for SCN. The regenerative treatment is HSCT (a procedure, not a drug). There are hematopoietic growth factors that stimulate white-cell production; of these, filgrastim products are the only ones approved for SCN. Below is a transparent summary:

1. Filgrastim (NEUPOGEN®) – FDA-approved for severe chronic neutropenia (including congenital); daily/twice-daily dosing to lift ANC and prevent infections. Function: stimulates neutrophil production. Mechanism: G-CSF receptor signaling expands granulopoiesis. FDA Access Data

2. Filgrastim-sndz (ZARXIO®) – FDA-approved biosimilar with SCN indication. Function/mechanism: as above. FDA Access Data

3. Filgrastim-aafi (NIVESTYM®) – FDA-approved biosimilar with SCN indication. Function/mechanism: as above. FDA Access Data

4. Filgrastim-ayow (RELEUKO®) – FDA-approved biosimilar with SCN indication; rare congenital cases need high doses; monitor closely. FDA Access Data

5. Sargramostim (LEUKINE®; GM-CSF) – Not approved for SCN; FDA-approved for AML/BMT recovery and H-ARS. Occasionally considered off-label if G-CSF unsuitable; requires specialist oversight due to fluid retention/capillary leak risks. FDA Access Data

6. Pegfilgrastim products (e.g., NEULASTA®) – Not approved for SCN; FDA-approved for chemotherapy-induced neutropenia and H-ARS. Listed to avoid confusion; routine SCN maintenance is filgrastim, not pegfilgrastim. FDA Access Data

---

Surgeries / procedures

1. Hematopoietic stem cell transplantation (HSCT) – Procedure: patient receives donor stem cells after conditioning; replaces defective marrow. Why: potential cure in patients who fail/tolerate poorly very high-dose G-CSF or who show clonal evolution. Note: Registries suggest earlier HSCT in ELANE patients requiring high G-CSF may lower leukemia risk. Nature

2. Incision & drainage of abscesses – Procedure: drain pus collections to control infection and obtain cultures. Why: antibiotics alone may not penetrate abscess cavities; drainage speeds recovery. PMC

3. Surgical management of complicated sinusitis/otitis – Procedure: ENT drainage when infections persist. Why: reduce bacterial load and prevent spread. PMC

4. Central venous access device placement (only if necessary) – Procedure: port/line for therapy and blood draws; strict sterile care. Why: reduces repeated sticks but increases infection risk; used judiciously. CDC

5. Dental procedures – Procedure: treat periodontal disease, extract non-salvageable teeth under antibiotic coverage when indicated. Why: mouth is a frequent infection source in SCN. NCBI

---

Preventions

• Keep all inactivated vaccines current; household members vaccinated. CDC

• Hand hygiene for everyone; teach proper technique. CDC

• Food safety (wash produce, cook meats fully; avoid unpasteurized foods). Andeal

• Dental care and daily mouth rinses. NCBI

• Prompt fever plan (≥38.3 °C once or ≥38.0 °C for 1 hr → urgent care). IDSA

• Skin care: moisturize, cover cuts, early review of redness/swelling. MedlinePlus

• Avoid probiotic products during severe neutropenia unless advised. ScienceDirect

• Masking in crowded clinics/outbreaks. CDC

• Regular CBC monitoring and registry follow-up (e.g., SCNIR). severe-chronic-neutropenia.org

• Genetic counseling for family planning. NCBI

---

When to see a doctor

• Immediately for fever: a single oral temp ≥38.3 °C (101 °F) or ≥38.0 °C (100.4 °F) for ≥1 hour, even if your child “looks okay.” Febrile neutropenia is an emergency. IDSA

• Same-day care for new mouth ulcers, worsening sore throat, painful urination, cough with breathing trouble, skin redness/warmth/swelling, or drainage from any wound. PMC

• Urgent review for persistent fevers despite antibiotics, severe bone pain/splenomegaly on G-CSF, or falls in ANC at usual doses. FDA Access Data

• Planned visits for dosing reviews, growth checks, and marrow surveillance to watch for rare pre-leukemic changes. PMC

---

What to eat / what to avoid

• Eat: well-washed fruits/vegetables; thoroughly cooked meats/eggs; pasteurized dairy; safely prepared grains/legumes; plenty of fluids; balanced calories and protein for growth. Why: supports healing and marrow health while minimizing microbe exposure. Andeal

• Avoid: unpasteurized milk/juice; undercooked meats/eggs; raw seafood; pre-cut refrigerated produce packs; salad bars/buffets; untreated water; probiotic drinks/yogurts/kefir unless your team approves. Why: higher germ loads or unclear safety in severe neutropenia. (Strict “neutropenic diets” offer no proven benefit; safe-handling is preferred.) Andeal+1

---

FAQs

1) What does “autosomal dominant” mean for our family?
One affected parent typically carries an ELANE change; each child has a 50% chance to inherit it. Genetic counseling explains testing and options. NCBI

2) Is ELANE the only cause?
No. ELANE is the most common autosomal-dominant cause; other genes and inheritance patterns exist. Genetic testing clarifies the exact cause. NCBI

3) How low is “severe” neutropenia?
ANC <500/µL is “severe” and carries the highest infection risk. Cleveland Clinic

4) What is the main treatment?
Filgrastim (G-CSF) products—the only FDA-approved therapy for SCN—raise neutrophil counts and prevent infections. FDA Access Data

5) What dose of filgrastim do congenital SCN patients start at?
Labels for filgrastim biosimilars specify 6 mcg/kg twice daily as a starting point for congenital neutropenia; doses are then individualized. FDA Access Data

6) Are pegfilgrastim shots used for SCN?
Pegfilgrastim is not approved for SCN maintenance; it’s for chemotherapy-induced neutropenia/H-ARS. SCN care uses filgrastim. FDA Access Data

7) Does long-term G-CSF cause leukemia?
Long follow-up shows SCN has a baseline risk of MDS/AML; after ~10 years on G-CSF, annual risk plateaus (~2.3%/year). G-CSF reduces sepsis deaths, revealing the underlying predisposition; high dose needs are a warning sign. PMC

8) Can SCN be cured?
HSCT can be curative and is considered when G-CSF response is poor or leukemia risk rises; data suggest early HSCT for ELANE patients needing high G-CSF may lower transformation risk. Nature

9) What infections are common?
Mouth/gum, skin/soft tissue, sinus/lung, liver abscesses; any fever is urgent. MedlinePlus

10) Do we need a “neutropenic diet”?
No strict “neutropenic diet.” Emphasize safe food handling; evidence does not support strict restrictions for infection prevention. Andeal+1

11) Are probiotics safe?
Not routinely in severe neutropenia; rare bloodstream infections have been reported, and benefits are unproven—avoid unless your team advises. ScienceDirect

12) What is the fever threshold we should use at home?
A single oral temp ≥38.3 °C (101 °F) or ≥38.0 °C (100.4 °F) for ≥1 hour. Seek care immediately. IDSA

13) Will my child lead a normal life?
With filgrastim, prompt fever care, and routine prevention, most children attend school and play normally, with common-sense precautions. Cincinnati Children’s

14) How often do we monitor labs?
Frequently at the start of G-CSF and after dose changes, then on a regular schedule set by your hematology team. FDA Access Data

15) Where can we learn more and connect with experts?
The Severe Chronic Neutropenia International Registry (SCNIR) provides education and tracks outcomes to improve care. severe-chronic-neutropenia.org

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 04, 2025.

PDF Documents For This Disease Condition References